Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonistFunded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101Year-end 2024 cash of approximately $415 million and extending cash runway guidance through year-e ...